Vnitr Lek 2018, 64(10):923-927 | DOI: 10.36290/vnl.2018.128

Some causes of poor adherence to long-term statin therapy and their solution

Vladimír Soška1,2,3,*, Ondřej Kyselák1
1 Oddělení klinické biochemie FN u sv. Anny v Brně
2 II. interní klinika LF MU a FN u sv. Anny v Brně
3 Katedra laboratorních metod LF MU, Brno

Statins are among the most important drugs in preventive cardiology because they greatly improve the prognosis of risk patients in both primary and secondary prevention of atherosclerotic cardiovascular disease. Adherence to long-term statin therapy is poor and decreases with the duration of statin use. A number of fake news about adverse effects of statins disseminated on the internet, such as damage of the brain, liver or kidney, contribute to worsening adherence. Statins therapy is sometimes unnecessary discontinued before planned surgery. The worse adherence to statin therapy may be also due to the fact that the patient does not know the connection between cholesterol lowering and improving his cardiovascular prognosis.

Keywords: adherence; brain; cholesterol; liver function; renal function; statins; surgery

Received: February 16, 2018; Accepted: March 23, 2018; Published: October 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Soška V, Kyselák O. Some causes of poor adherence to long-term statin therapy and their solution. Vnitr Lek. 2018;64(10):923-927. doi: 10.36290/vnl.2018.128.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670-1681. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(10)61350-5>. Go to original source... Go to PubMed...
    2. Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 23(11): NP1-NP96. Dostupné z DOI: <http://dx.doi.org/10.1177/2047487316653709>. Go to original source... Go to PubMed...
    3. Skoupá J. Dlouhodobá adherence ke kardiovaskulární farmakoterapii v České republice na příkladu amlodipinu a atorvastatinu. Kapitoly z kardiologie 2011; 3(2): 63-67. Dostupné z WWW: <https://www.tribune.cz/clanek/23155-dlouhodoba-adherence-ke-kardiovaskularni-farmakoterapii-v-ceske-republice-na-prikladu-amlodipinu-a-atorvastatinu>.
    4. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. Jama 2002; 288(4): 462-467. Go to original source... Go to PubMed...
    5. Chowdhury R, Khan H, Heydon E et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013; 34(38): 2940-2948. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/eht295>. Go to original source... Go to PubMed...
    6. Soška V, Kyselák O. Lze zlepšit komplianci pacientů k dlouhodobé terapii statiny? Vnitř Lék 2017; 63(10): 663-666. Go to original source... Go to PubMed...
    7. Schouten O, Kertai MD, Bax JJ et al. Safety of Perioperative statin use in high-risk patients undergoing major vascular surgery. Am J Cardiol 2005; 95(5): 658-660. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2004.10.046>. Go to original source... Go to PubMed...
    8. Xia J, Qu Y, Yin C et al. Preoperative rosuvastatin protects patients with coronary artery disease undergoing noncardiac surgery. Cardiology 2015; 131(1): 30-37. Dostupné z DOI: <http://dx.doi.org/10.1159/000371872>. Go to original source... Go to PubMed...
    9. Lindenauer PK, Pekow P, Wang K et al. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 2004; 291(17): 2092-2099. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.291.17.2092>. Go to original source... Go to PubMed...
    10. Paraskevas KI, Liapis CD, Hamilton G et al. Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery? Eur J Vasc Endovasc Surg 2006; 32(3): 286-293. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejvs.2006.03.009>. Go to original source... Go to PubMed...
    11. Sanders RD, Nicholson A, Lewis SR et al. Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery. Cochrane Database Syst Rev 2013; (7): CD009971. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD009971.pub2>. Go to original source... Go to PubMed...
    12. McGirt MJ, Perler BA, Brooke BS et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy. J Vasc Surg 2005; 42(5): 829-836; discussion 836-827. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jvs.2005.08.039>. Go to original source... Go to PubMed...
    13. Cosio FG, Pesavento TE, Pelletier RP et al. Patient survival after renal transplantation III: The effects of statins. Am J Kidney Dis 2002; 40(3): 638-643. Dostupné z DOI: <http://dx.doi.org/10.1053/ajkd.2002.34927>. Go to original source... Go to PubMed...
    14. Wenke K, Meiser B, Thiery J et al. Impact of simvastatin therapy after heart transplantation an 11-year prospective evaluation. Herz 2005; 30(5): 431-432. Dostupné z DOI: <http://dx.doi.org/10.1007/s00059-005-2685-6>. Go to original source... Go to PubMed...
    15. Johnson BA, Iacono AT, Zeevi A et al. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 2003; 167(9): 1271-1278. Dostupné z DOI: <http://dx.doi.org/10.1164/rccm.200205-410OC>. Go to original source...
    16. Ward RP, Leeper NJ, Kirkpatrick JN et al. The effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. Int J Cardiol 2005; 104(3): 264-268. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2004.10.030>. Go to original source... Go to PubMed...
    17. Sai C, Li J, Yingbin X et al. Atorvastatin Prevents Postoperative Atrial Fibrillation for Patients undergoing Cardiac Surgery. Hellenic J Cardiol 2018: pii: S1109-9666(17)30450-5. Dostupné z DOI: <http://dx.doi.org/10.1016/j.hjc.2017.12.012>. Go to original source... Go to PubMed...
    18. de Waal BA, Buise MP, van Zundert AA. Perioperative statin therapy in patients at high risk for cardiovascular morbidity undergoing surgery: a review. Br J Anaesth 2015; 114: 44-52. Dostupné z DOI: <http://dx.doi.org/10.1093/bja/aeu295>. Go to original source...
    19. An JH, Shi FW, Liu S et al. Preoperative statins as modifiers of cardiac and inflammatory outcomes following coronary artery bypass graft surgery: a meta-analysis. Interact Cardiovasc Thorac Surg 2017; 25(6): 958-965. Dostupné z DOI: <http://dx.doi.org/10.1093/icvts/ivx172>. Go to original source... Go to PubMed...
    20. Fransgaard T, Thygesen LC, Gogenur I. Statin use is not associated with improved 30-day survival in patients undergoing surgery for colorectal cancer. Int J Colorectal Dis 2018; 33(2): 199-207. Dostupné z DOI: <http://dx.doi.org/10.1007/s00384-017-2947-9>. Go to original source... Go to PubMed...
    21. Catapano AL, Reiner Z, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217(1): 3-46. Go to original source... Go to PubMed...
    22. Tziomalos K, Athyros VG, Paschos P et al. Nonalcoholic fatty liver disease and statins. Metabolism 2015; 64(10): 1215-1223. Dostupné z DOI: <http://dx.doi.org/10.1016/j.metabol.2015.07.003>. Go to original source... Go to PubMed...
    23. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34(3): 274-285. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365-2036.2011.04724.x>. Go to original source... Go to PubMed...
    24. Piepoli MF, Hoes AW, Agewall S et al. [Authors/Task Force Members]. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016; 252: 207-274. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2016.05.037>. Go to original source... Go to PubMed...
    25. Athyros VG, Tziomalos K, Gossios TD et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376(9756): 1916-1922. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(10)61272-X>. Go to original source... Go to PubMed...
    26. Tikkanen MJ, Fayyad R, Faergeman O et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013; 168(4): 3846-3852. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2013.06.024>. Go to original source... Go to PubMed...
    27. Athyros VG, Alexandrides TK, Bilianou H et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017; 71: 17-32. Dostupné z DOI: <http://dx.doi.org/10.1016/j.metabol.2017.02.014>. Go to original source... Go to PubMed...
    28. Del Ben M, Baratta F, Polimeni L et al. Under-prescription of statins in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2017; 27(2): 161-167. Dostupné z DOI: <http://dx.doi.org/10.1016/j.numecd.2016.09.011>. Go to original source... Go to PubMed...
    29. Palmer SC, Navaneethan SD, Craig JC et al. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database of Systematic Reviews 2014; (1): CD005019. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD005019.pub4>. Go to original source... Go to PubMed...
    30. Barylski M, Nikfar S, Mikhailidis DP et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy - a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res 2013; 72: 35-44. Dostupné z DOI: <http://dx.doi.org/10.1016/j.phrs.2013.03.007>. Go to original source... Go to PubMed...
    31. LipFix (atorvastatin). Souhrn údajů o přípravku. SÚKL 2016; sp.zn.sukls96124/2016. Dostupné z WWW: <http://sukl.cz>.
    32. Qin X, Dong H, Fang K et al. The effect of statins on renal outcomes in patients with diabetic kidney disease: A systematic review and meta-analysis. Diabetes Metab Res Rev 2017; 33(6): e2901. Dostupné z DOI: <http://dx.doi.org/10.1002/dmrr.2901>. Go to original source... Go to PubMed...
    33. Zhang Z, Wu P, Zhang J et al. The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A meta-analysis. Pharmacol Res 2016; 105: 74-83. Dostupné z DOI: <http://dx.doi.org/10.1016/j.phrs.2016.01.005>. Go to original source... Go to PubMed...
    34. Geng Q, Ren J, Song J et al. Meta-analysis of the effect of statins on renal function. Am J Cardiol 2014; 114(4): 562-570. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2014.05.033>. Go to original source... Go to PubMed...
    35. Zhang J, Liu Q. Cholesterol metabolism and homeostasis in the brain. Protein Cell 2015; 6(4): 254-264. Dostupné z DOI: <http://dx.doi.org/10.1007/s13238-014-0131-3>. Go to original source... Go to PubMed...
    36. Olsson AG, Angelin B, Assmann G et al. Can LDL cholesterol be too low? Possible risks of extremely low levels. J Intern Med 2017; 281(6): 534-553. Dostupné z DOI: <http://dx.doi.org/10.1111/joim.12614>. Go to original source... Go to PubMed...
    37. McFarland AJ, Anoopkumar-Dukie S, Arora DS et al. Molecular mechanisms underlying the effects of statins in the central nervous system. Int J Mol Sci 2014; 15(11): 20607-20637. Dostupné z DOI: <http://dx.doi.org/10.3390/ijms151120607>. Go to original source... Go to PubMed...
    38. Karam JG, Loney-Hutchinson L et al. [Stroke Prevetion by Aggressive Reduction in Cholestrol Levels Investigators]. High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. J Cardiometab Syndr 2008; 3(1): 68-69. Go to original source... Go to PubMed...
    39. Sheng Z, Jia X, Kang M. Statin use and risk of Parkinson's disease: A meta-analysis. Behav Brain Res 2016; 309: 29-34. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bbr.2016.04.046>. Go to original source... Go to PubMed...
    40. Saeedi Saravi SS, Saeedi Saravi SS, Arefidoust A et al. The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration. Metab Brain Dis 2017; 32(4): 949-965. Dostupné z DOI: <http://dx.doi.org/10.1007/s11011-017-0021-5>. Go to original source... Go to PubMed...
    41. Geifman N, Brinton RD, Kennedy RE et al. Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease. Alzheimers Res Ther 2017; 9(1): 10. Dostupné z DOI: <http://dx.doi.org/10.1186/s13195-017-0237-y>. Go to original source... Go to PubMed...
    42. Swiger KJ, Manalac RJ, Blumenthal RS et al. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc 2013; 88(11): 1213-1221. Dostupné z DOI: <http://dx.doi.org/10.1016/j.mayocp.2013.07.013>. Go to original source... Go to PubMed...
    43. Parsaik AK, Singh B, Murad MH et al. Statins use and risk of depression: a systematic review and meta-analysis. J Affect Disord 2014; 160: 62-67. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jad.2013.11.026>. Go to original source... Go to PubMed...
    44. Salagre E, Fernandes BS, Dodd S et al. Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials. J Affect Disord 2016; 200: 235-242. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jad.2016.04.047>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.